Pharmaceuticals France

France Compounded Weight Loss Medications Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

France Compounded Weight Loss Medications Market Industry Trends and Forecast to 2034: Segmented by (Drug, Channel, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

France · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $41.7 Mn Placeholder estimate
Estimate 2025 $46.2 Mn 2.6% of the global market
Projected 2034 $116.2 Mn 151.7% Adds $70.0 Mn over 9 forecast years
CAGR 2025–2034 10.8% Faster than 66% of 180 Pharmaceuticals markets here
Key players 5 Companies profiled
  • France is 2.63% of the global market.
  • In Europe, the largest is Germany at $68.9 Mn.
  • Fastest growing: Russia at 11.7% a year.
  • France ranks 3rd of 6 by size in Europe.

Market size projection

France

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$70.0 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Compounded Weight Loss Medications Market market size by year, France
YearMarket sizeChange that yearSince 2025
2024 (estimate) $41.7 Mn — —
2025 (base) $46.2 Mn +$4.5 Mn —
2026 (forecast) $51.1 Mn +$5.0 Mn +10.8%
2027 (forecast) $56.7 Mn +$5.5 Mn +22.8%
2028 (forecast) $62.8 Mn +$6.1 Mn +36%
2029 (forecast) $69.6 Mn +$6.8 Mn +50.7%
2030 (forecast) $77.1 Mn +$7.5 Mn +67%
2031 (forecast) $85.4 Mn +$8.3 Mn +85%
2032 (forecast) $94.6 Mn +$9.2 Mn +105%
2033 (forecast) $104.9 Mn +$10.2 Mn +127.2%
2034 (forecast) $116.2 Mn +$11.3 Mn +151.7%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

France Compounded Weight Loss Medications Market Analysis at a glance
Market size, 2025$46.2 Mn placeholder estimate
Forecast, 2034$116.2 Mn placeholder estimate
Growth (CAGR), 2025–203410.8% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug, channel and end user (see all)
Key playersHims & Hers Health, Ro, Empower Pharmacy, Noom, WeightWatchers (see all)
Regulator in FranceANSMSource: ANSM, French medicines agency. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The France Compounded Weight Loss Medications Market Analysis Executive Summary

Compounded weight loss medications are pharmacy-prepared versions of weight-loss drugs, made for individual patients, often during shortages of branded products.

Key segments of the compounded Weight Loss Medications market include drug (Compounded Semaglutide, Compounded Tirzepatide and Others) and channel (Compounding Pharmacies, Telehealth Platforms and Clinics).

Bar chart: France Compounded Weight Loss Medications market size, 2024–2034, placeholder estimates. $41.7 Mn in 2024, $46.2 Mn in 2025 and $116.2 Mn in 2034, 10.8% CAGR.
France Compounded Weight Loss Medications market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

France Compounded Weight Loss Medications Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the compounded Weight Loss Medications market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the compounded Weight Loss Medications market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the compounded Weight Loss Medications market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for Compounded Weight Loss Medications Market in France

The compounded Weight Loss Medications market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Compounded Weight Loss Medications Market in France

Compounded Weight Loss Medications in France: rules, payment and health figures

Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by ANSM, the French medicines agency.⁠[1] National health insurance (Assurance Maladie) pays back part of most care costs, and the HAS, the French National Authority for Health, advises on what it should cover.⁠[2] Obesity (adults): 11.2% of adults in 2024, the latest WHO figure for France.⁠[3]

[1] ANSM, French medicines agency. Checked 14 Nov 2026.

[2] Assurance Maladie (ameli.fr). Checked 14 Nov 2026.

[3] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 15 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for compounded Weight Loss Medications. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in France.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Compounded Weight Loss Medications right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Compounded Weight Loss Medications in context

France compared

  • Obesity (adults): 11.2% of adults (2024). World: 16.2% of adults (2024). 6th highest of the 6 countries we cover in Europe.[1]
  • Health spending per person: 5,327 US$ per person (2024). World: 1,317 US$ per person (2023). 3rd highest of the 6 countries we cover in Europe.[2]
  • Doctors: 3.28 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 6th highest of the 6 countries we cover in Europe.[3]

[1] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 15 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Compounded Weight Loss Medications market in France?
Placeholder estimate: about $46.2 Mn in 2025, rising to about $116.2 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Compounded Weight Loss Medications market in France growing?
Placeholder estimate: about 10.8% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Compounded Weight Loss Medications market report cover?
The report splits the market by drug (Compounded Semaglutide, Compounded Tirzepatide, Others), channel (Compounding Pharmacies, Telehealth Platforms, Clinics) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Compounded Weight Loss Medications market?
Key players include Hims & Hers Health, Ro, Empower Pharmacy, Noom and WeightWatchers.
What is driving the Compounded Weight Loss Medications market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the compounded Weight Loss Medications market.
Who regulates Compounded Weight Loss Medications in France?
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by ANSM, the French medicines agency. Source: ANSM, French medicines agency. Checked 14 Nov 2026.
How is healthcare paid for in France?
National health insurance (Assurance Maladie) pays back part of most care costs, and the HAS, the French National Authority for Health, advises on what it should cover. Source: Assurance Maladie (ameli.fr). Checked 14 Nov 2026.
What does WHO report for France?
Obesity (adults): 11.2% of adults in 2024, the latest WHO figure. Source: WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 15 Nov 2026.
How many people in France are 65 or older?
22.5% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 15 Nov 2026.
How much research is published on Compounded Weight Loss Medications?
PubMed lists 9 papers on Compounded Weight Loss Medications added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in France

See all

Related on obesity and pharmacy and generics

See the topic